Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

February 19, 2020February 19, 2020

Onvansertib’s Addition Aids Responses to Zytiga Even in Resistant Patients, New Trial Data Show

News

Trovagene’s investigational oral therapy onvansertib helps overcome resistance to Zytiga (abiraterone acetate) in men with metastatic castration-resistant prostate cancer (mCRPC), latest data from a Phase 2 clinical trial show. These results also ... Read more

February 11, 2020February 13, 2020

Xtandi Significantly Improves Overall Survival in Men with High-risk CRPC, Phase 3 Final Data Show

News

Treatment with Xtandi (enzalutamide) significantly extends the lives of men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), according to final data from a Phase 3 clinical trial. Developed by Pfizer and Astellas Pharma, ... Read more

January 23, 2020January 23, 2020

Exelixis to Expand Group of mCRPC Patients in Phase 1b Trial Testing Cabometyx-Tecentriq Combo

News

Exelixis will expand its Phase 1b clinical trial evaluating a combination of Cabometyx (cabozantinib) with Tecentriq (atezolizumab) to include more patients with metastatic castration-resistant prostate cancer (mCRPC), based on ... Read more

January 16, 2020January 16, 2020

Rubraca Granted FDA Priority Review for Advanced Prostate Cancer with BRCA Mutations

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Clovis Oncology’s application seeking approval of Rubraca (rucaparib) for treating men with recurrent metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations. The priority review ... Read more

January 13, 2020January 13, 2020

Veyonda Plus Low-dose Radiotherapy May Halt Disease Progression in Late-Stage PC, Study Suggests

News

Noxopharm’s Veyonda (idronoxil), in combination with low-dose radiation therapy, safely halted disease progression and eased pain in men with late-stage metastatic castration-resistant prostate cancer (mCRPC), according to results from a Phase 1b ... Read more

December 30, 2019January 9, 2020

PyL Imaging Agent Accurately Detects Recurrent Prostate Cancer Lesions, Trial Shows

News

Progenics Pharmaceuticals’ PyL, a new imaging agent for positron emission tomography (PET) scans, can accurately detect the location of recurrent prostate cancer lesions, according to data from a Phase 3 clinical trial. ... Read more

December 19, 2019December 19, 2019

Lynparza Particularly Effective in Prostate Cancer Patients Carrying BRCA Mutations, Phase 2 Study Shows

News

Lynparza (olaparib), a breast and ovarian cancer treatment, is also showing promising results in men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in DNA repair genes, particularly ... Read more

December 3, 2019January 2, 2020

Keytruda Shows Promise for Some with Highly Advanced Prostate Cancer in Phase 2 Trial

News

The immunotherapy Keytruda (pembrolizumab) extended for at least two years the lives of a small proportion of men with metastatic castration-resistant prostate cancer (mCRPC) who had exhausted all other treatment options, data ... Read more

November 11, 2019

Men with BRCA2 Mutations Should Get Regular PSA Screening, Phase 3 Interim Data Suggest

News

Prostate-specific antigen (PSA) testing — a controversial approach to detecting prostate cancer — spotted the cancer more often, at a younger age, and in more serious forms in men ... Read more

October 31, 2019

Prostate Cancer Patients May Benefit from Routine Tumor Genetic Testing, Study Suggests

News

Implementation of routine tumor genetic testing may help identify the approximately 30% of men with metastatic castration-resistant prostate cancer (mCRPC) who may significantly benefit from targeted treatment, namely PARP ... Read more

Pin It on Pinterest